Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News PolyPid Ltd PYPD

Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.

Recent & Breaking News (NDAQ:PYPD)

PolyPid to Report Third Quarter 2021 Financial Results and Operational Highlights on November 10, 2021

GlobeNewswire November 1, 2021

PolyPid to Present at Upcoming Cantor Fitzgerald Global Healthcare Conference

GlobeNewswire September 20, 2021

PolyPid Announces Positive Preclinical Data of its Intra-tumoral OncoPLEX in Brain Cancer

GlobeNewswire September 13, 2021

PolyPid to Present at First World Association Against Infection in Orthopaedics and Trauma Congress

GlobeNewswire August 17, 2021

Poly Changes NYSE Ticker Symbol from "PLT" to "POLY"

PR Newswire May 24, 2021

Poly Announces NYSE Ticker Symbol Change from "PLT" to "POLY"

PR Newswire May 13, 2021

Continued Progress but Weaker Demand in Europe for the Quarter

PR Newswire August 9, 2019